Kidney Cancer

Share this journal
Kidney Cancer - journal
ISSN print
ISSN online
4; 4 issues
Last issue (4:s1) published on 25 February 2020
Next issue
4:1 scheduled for May 2020
Back volumes
Cancer Research, Medicine & Health, Urology

APCs Waived Article processing charges (APCs) are currently waived for Kidney Cancer, and content is currently published as Open Access.

Sign Ups & Social Media –
Be sure to sign up to the KCA journal newsletter to receive alerts of new issues and other journal news. Sign up via this link & you can read the latest newsletter here. To follow us on social media, find our Twitter account at @KCA_Journal and keep updated as we share our journal content and news of interest to the kidney cancer research community. And, importantly, you can join in the discussion with our research community!

Kid .Can. Assoc. Partnership –
As of Nov 2017, a new partnership was announced between the Kidney Cancer Association ( and our journal Kidney Cancer, which is a forum for important scientific advancements and the advocacy community.

Kidney Cancer is an international multidisciplinary journal to facilitate progress in understanding the epidemiology/etiology, genetics, molecular correlates, pathogenesis, pharmacology, ethics, patient advocacy and survivorship, diagnosis and treatment of tumors of the kidney. The journal publishes research reports, reviews, short communications, and letters-to-the-editor. The journal is dedicated to providing an open forum for original research in basic science, translational research and clinical medicine that will expedite our fundamental understanding and improve treatment of tumors of the kidney.


Primo N. Lara, Jr., MD
University of California Davis Comprehensive Cancer Center
Sacramento, CA, USA

Peter Mulders, MD, PhD
Radboud UMC
Nijmegen, The Netherlands

Associate Editors

Neeraj Agarwal, MD
Huntsman Cancer Institute, University of Utah, Salt Lake City, USA

Axel Bex, MD, PhD
Netherlands Cancer Institute, Amsterdam, The Netherlands

Toni K. Choueiri, MD
Dana-Farber Cancer Institute, Boston, USA

Enrique Grande, MD
Anderson Cancer Center Madrid, Madrid, Spain

Viktor Grünwald, MD
University Hospital Essen, Essen, Germany

Eric Jonasch, MD
The University of Texas MD Anderson Cancer Center, Houston, USA

Bradley C. Leibovich, MD
Mayo Clinic, Rochester, USA

Egbert Oosterwijk, PhD
Radboud UMC, Nijmegen, The Netherlands

Javier Puente, MD, PhD
Hospital Clinico Universitario San Carlos, Madrid, Spain

Sandy Srinivas, MD
Stanford University, Stanford, USA

Yoshihiko Tomita, MD, PhD
Niigata University, Niigata, Japan

Hirotsugu Uemura, MD, PhD
Kindai University Faculty of Medicine, Osaka, Japan

Christopher G. Wood, MD
The University of Texas MD Anderson Cancer Center, Houston, USA

Social Media Editor

Neeraj Agarwal, MD
Huntsman Cancer Institute, University of Utah, Salt Lake City, USA

Associate Editor for Reviews

Sumanta Pal, MD
City of Hope, Duarte, USA

Editor of Clinical Trials Corner

Mamta Parikh, MD
UC Davis Comprehensive Cancer Center, Sacramento, USA

Editorial Board

Hideyuki Akaza, MD
University of Tokyo, Tokyo, Japan

Georg A. Bjarnason, MD, FRCP(C)
Sunnybrook Odette Cancer Center, Toronto, Canada

William P. Bro
Kidney Cancer Association, Chicago, USA

James Brugarolas, MD, PhD
University of Texas Southwestern Medical Center, Dallas, USA

Ronald M. Bukowski, MD
Cleveland Clinic Foundation, Cleveland, USA

Steven C. Campbell, MD, PhD
Cleveland Clinic, Cleveland, USA

Marc Dall’era, MD
UC Davis Comprehensive Cancer Center, Sacramento, USA

Tanya B. Dorff, MD
City of Hope, Duarte, USA

Janice P. Dutcher, MD
Cancer Research Foundation, Chappaqua, USA

Tim Eisen, PhD
University of Cambridge, Cambridge, United Kingdom

Bernard Escudier, MD
Institut Gustave Roussy, Villejuif, France

Robert A. Figlin, MD
Cedars-Sinai Medical Center, Los Angeles, USA

Thomas (Tom) Flaig, MD
University of Colorado School of Medicine, Aurora, USA

Jorge Garcia, MD
Cleveland Clinic, Cleveland, USA

Dan George, MD
Duke University School of Medicine, Durham, USA

Ugo De Giorgi, MD
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy

Martin Gore, PhD
The Royal Marsden Hospital and Instuitute of Cancer Research, London, United Kingdom

Rudolfo De Guzman, MD
National Kidney and Transplant Institute, Metro Manila, Philippines

John Haanen, MD, PhD
Netherlands Cancer Institute, Amsterdam, The Netherlands

Naomi Haas, MD
University of Pennsylvania, Philadelphia, USA

Hans Hammers, MD, PhD
University of Texas Southwestern, Dallas, USA

Michael R. Harrison, MD
Duke Cancer Institute, Durham, USA

Daniel Heng, MD, MPH
Tom Baker Cancer Center, Calgary, Canada

Michelle S. Hirsch, MD, PhD
Brigham and Women's Hospital, Harvard Medical School, Boston, USA

James J. Hsieh, MD, PhD
Washington University School of Medicine, St. Louis, USA

Thomas Hutson, DO, PharmD
US Oncology/Baylor, Houston, USA

Choung Soo Kim, MD, PhD
Asan Medical Center, Seoul, South Korea

Won Kim, MD
University of California San Francisco, San Francisco, USA

Christian Kollmannsberger, MD
BC Cancer Agency, Vancouver, Canada

James Larkin, MD, PhD
The Institute of Cancer Research, London, United Kingdom

Marston Linehan, MD
National Cancer Institute, Bethesda, USA

Borje Ljungberg, MD, PhD
Umeå University, Umeå, Sweden

Axel S. Merseburger, MD, PhD
University Hospital Schleswig-Holstein, Lübeck, Germany

Moshe C. Ornstein, MD
Cleveland Clinic, Cleveland, OH, USA

Susanne Osanto, MD, PhD
Leiden University Medical Center, Leiden, The Netherlands

Stephane Oudard, MD, PhD
Hôpital Européen Georges Pompidou, Paris, France

Allan J. Pantuck, MD
UCLA Institute of Urologic Oncology, Los Angeles, USA

Mamta Parikh, MD
University of California Davis Comprehensive Cancer Center, Sacramento, USA

Elizabeth Plimack, MD
Fox Chase Cancer Center, Philadelphia, USA

Camillo Porta, MD
IRCCS San Matteo University Hospital Foundation, Pavia, Italy

Thomas Powles, MD
The Royal Free NHS Trust and Barts Cancer Institute, London, United Kingdom

David I. Quinn, MBBS, PhD
University of Southern California Norris Comprehensive Cancer Center, Los Angeles, USA

W. Kimryn (Kim) Rathmell, MD, PhD
Vanderbilt-Ingram Cancer Center, Nashville, USA

Bruce G. Redman, MD
University of Michigan, Ann Arbor, USA

Brian Rini, MD
Cleveland Clinic, Cleveland, USA

Paul Russo, MD
Memorial Sloan Kettering Cancer Center, New York, USA

Christopher Ryan, MD
Oregon Health Science University, Portland, USA

Manuela Schmidinger, MD
University of Austria, Vienna, Austria

Brian Shuch, MD
Yale School of Medicine/Smilow Cancer Center, New Haven, USA

Ramaprasad Srinivasan, MD, PhD
National Cancer Institute, Bethesda, USA

Walter Stadler, MD
University of Chicago, Chicago, USA

Mark Stein, MD
Rutgers, The State University of New Jersey, New Brunswick, USA

Cora N. Sternberg, MD
San Camillo and Forlanini Hospitals, Rome, Italy

Cezary Szczylik, MD, PhD
Oncology Military Medical Institute, Warsaw, Poland

Nizar M. Tannir, MD
MD Anderson Cancer Center, Houston, USA

Ilya Tsimafeyeu, MD
Kidney Cancer Research Bureau, Russian Society of Clinical Oncology, Moscow, Russia

Robert G. Uzzo, MD
Fox Chase Cancer Center, Philadelphia, USA

Ulka Vaishampayan, MD
Wayne State University, Karmanos Cancer Institute, Detroit, USA

Gretchen Vaughan
Kidney Cancer Association, Chicago, IL, USA

Guillermo de Velasco, MD, PhD
Hospital Universitario 12 de Octubre, Madrid, Spain

Nicholas J. Vogelzang, MD
Comprehensive Cancer Centers of Nevada (CCCN), Las Vegas, USA

Martin H. Voss, MD
Memorial Sloan Kettering Cancer Center, New York, USA

Stenio Zequi, MD, PhD
AC Camargo Cancer Center, Sao Paulo, Brazil



By submitting my article to this journal, I agree to the IOS Press License to Publish: and the IOS Press Privacy Policy:

Authors are requested to submit their manuscript electronically to the online submission system msTracker.

Note that the manuscript should be uploaded as one file with tables and figures included. This file can be a Word document, a PDF, or an embedded or zip file (.rar) if separate high resolution figures or a supplemental file such as a video are also to be included with the submission (the file size maximum for a video is 25MB). If the video is too large to submit, please contact to arrange a file transfer. For further information, see “Supplementary Data” below.

Resubmissions should clearly mention that the submission is a revision and include the reference number in the cover letter. The author's replies to the reviewer comments should be included in the revised manuscript itself (at the top). The revised paper should always be a Word document.

Submission of an article is understood to imply that the article is original and unpublished and is not being considered for publication elsewhere. Kidney Cancer is committed to the highest ethical standards and best practices in publishing and follows the code of conduct for Committee on Publication Ethics/DOAJ and the ICMJE. Any possible conflict of interest, financial or otherwise, related to the submitted work must be clearly indicated in the manuscript (for further details see Procedures involving experiments on human subjects should be in accord with the ethical standards of the Committee on Human Experimentation of the institution in which the experiments were done or in accord with the Helsinki Declaration of 1975. Procedures involving experimentation on animal subjects should be in accord with either the guide of the institution in which the experiments were done, or with the National Research Council’s guide for the care and use of laboratory animals.

If the address to which proofs should be sent is different from the correspondence address, authors are kindly requested to indicate this. Both the editor and the publisher should be informed of any changes in either or both of these addresses. Please also supply a direct telephone number and a fax number, if available.


Research Reports

Organization and style of presentation
Manuscripts must be written in US English. Authors whose native language is not English are recommended to seek the advice of a native English speaker or English language service before submitting their manuscripts. A language or editing service that we recommend is PeerWith.

Manuscripts should be double spaced throughout with wide margins (2.5cm or 1in), including the abstract and references. Every page of the manuscript, including the title page, references, tables, etc., should include a page number centered at the bottom.

Manuscripts should be organized in the following order with headings and subheadings typed on a separate line, without indentation. 

Title Page

  1. Title (should be clear, descriptive and concise).
  2. Full name(s) of author(s) and higher degrees.
    All authors should meet the following 4 criteria: (a) have made substantial contributions to the work, (conception, performance or interpretation of data); (b) writing the article; (c) approve the final version to be published; (d) agreed to be accountable for the accuracy and integrity of the work. 
  3. Full affiliation(s). Delineate affiliations with lowercase letters.
  4. Present address of author(s), if different from affiliation.
  5. Running title (45 characters or less, including spaces).
  6. Complete correspondence address, including telephone number, fax number and e-mail address.

Leave the author information blank if double-blind peer review is wished for, but do include the information in the submission letter to the editor.

Abstract and Keywords
The abstract for research papers should follow the “structured abstract” format:
The abstract should try to be no longer than 250 words. 
For other papers such as Reviews, the abstract should be clear, descriptive, and self-explanatory, and no longer than 250 words.
Include a list of 4-10 keywords. These keywords should be terms from the MeSH database.
The abstract should make clear the context and aims for the study.  It should also state how it was conducted, the main findings and conclusions drawn. Clinical trial abstracts should include items deemed essential by the CONSORT group.

This should outline the context for and purpose of the study.

Materials and Methods
There is no word limit to the materials and methods section, as the journal’s policy is that methodological rigour and reproducibility is of great importance. This section should aim to be sufficiently detailed to enable others with access to the data to reproduce the results.

Cell line identity 
In keeping with scientific consensus guidelines, the Journal considers it to be good practice for cultured cell lines to be authenticated. For each cell line, authors should include in the Methods section a statement that specifies:

  1. Source of the cell lines
  2. Are any cell lines used in this paper listed in the database of commonly misidentified cell lines maintained by the International Cell Line Authentication Committee (ICLAC)? If yes, include in the Methods section a scientific justification of their use
  3. If the cell lines been authenticated and by which method
  4. If the cell lines been tested for mycoplasma contamination and if so, date last tested

Microarray Data
The Journal has adopted the microarray data standard developed by the Microarray Gene Expression Data Society (MGED), requiring that all authors using microarray data analysis in their research submit a complete data set to the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus database (GEO; prior to manuscript submission. Papers submitted to the Journal that use microarray data analysis must comply with the “minimum information about microarray experiments” (MIAME) standard. Access to the GEO database is free and open for all, and the database is maintained by NCBI (Cheadle C, Cho-Chung YS, Becker KG, and Vawter MP. Application of z-score transformation to Affymetrix data. Appl Bioinformatics. 2003; 2(4): 209-217.)

These should be presented in a logical order and summarize the salient findings.

This should link the conclusions with the aims of the study but avoid overinterpreting the study’s findings.

Acknowledgments including sources of support

Conflict of Interest
If there is no conflict of interest to declare, do still include this section and insert “The authors have no conflict of interest to report”.


  • Place citations as numbers in square brackets in the text. All publications cited in the text should be presented in a list of references following the text of the manuscript. Only articles published or accepted for publication should be listed in the reference list. Submitted articles can be listed in the text as (Author(s), unpublished data).
  • All authors should be listed in the reference list.
  • References should be listed in the order of appearance in Vancouver style: 

[1] Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349(9):859-66.
[2] Murray PR, Rosenthal KS, Kobayashi GS, Pfaller MA. Medical microbiology. 4th ed. St. Louis: Mosby; 2002.
[3] Berkow R, Fletcher AJ, editors. The Merck manual of diagnosis and therapy. 16th ed. Rahway (NJ): Merck Research Laboratories; 1992.
[4] Meltzer PS, Kallioniemi A, Trent JM. Chromosome alterations in human solid tumors. In: Vogelstein B, Kinzler KW, editors. The genetic basis of human cancer. New York: McGrawHill; 2002. p. 93113.
[5] Canadian Cancer Society [homepage on the Internet]. Toronto: The Society; 2006 [updated 2006 May 12; cited 2006 Oct 17]. Available from:

Number according to their sequence in the text. The text should include references to all tables.
Provide each table on a separate page of the manuscript after the references.
Include a brief and self-explanatory title with any explanations essential to the understanding of the table given in footnotes at the bottom of the table.
Vertical lines should not be used to separate columns. Leave some extra space between the columns instead.

Figure Legends
The author is required to have obtained patient permission from all recognizable participants in photographs, videos, or other information that may be published in the Journal or on the journal’s website. A statement that permission was granted by the patient must accompany the figure legend. Do not use study participants' names, initials, or hospital numbers in the legend, figure, or anywhere in the manuscript.

Number the figures according to their sequence in the text. The text should include references to all figures.
For the file formats of the figures please take the following into account:

  • Line art should have a minimum resolution of 1200 dpi, save as EPS or TIFF.
    - Do not use faint lines and/or lettering and check that all lines and lettering within the figures are legible at final size.
    - All lines should be at least 0.1 mm (0.3 pt) wide.
    - Vector graphics containing fonts must have the fonts embedded in the files.
  • Grayscales (incl photos) should have a minimum resolution of 300 dpi, or 600 dpi for combination art (lettering and images); save as TIFF.
  • Do not save figures as JPEG, this format may lose information in the process
  • Do not use figures taken from the Internet, the resolution will be too low for printing
  • Do not use color in your figures if they are to be printed in black & white, as this will reduce the print quality (note that in software often the default is color, you should change the settings)
  • For figures that should be printed in color, please send a CMYK encoded EPS or TIFF

Figures should be designed with the format of KCA in mind and preferable sized as they will appear when printed. A single column of the journal is 77mm and two columns are 165mm.

Figures should be cropped to include the figure only (no blank space).

On figures where a scale is needed, use bar scales to avoid problems if the figure needs to be reduced.

Each illustration should have a brief self-explanatory legend that should be typed separately from the figure in the section of the manuscript following the tables.

Costs for color figures in the print version of the journal are as follows: 1 figure - 650 euro; 2 figures - 900 euro; 3 figures - 1050 euro; 4 figures - 1200 euro; 5 figures - 1350 euro. Cost for each additional color figure will be 150 euro. Color figures are free in the electronic version of the journal. You may opt to send in both black/white figures for print, and color figures for the online PDF (please adjust the figure legend appropriately).

Supplementary Data
Supplementary data can be submitted with the manuscript, included within the manuscript after the Figures and Tables (or otherwise after the References). Each supplementary item should have a legend and should not exceed the file size of 10MB. Supplemental videos can be submitted separately (see top of page for submission guidelines of videos). A short description of the supplementary items should be included under the header of “Supplementary Material” within the manuscript before the “References”. Large datasets should be hosted on the author’s own or institute’s website or in an appropriate database, and should be properly cited within the manuscript.

Reviews should be authoritative and topical and provide comprehensive and balanced coverage of a timely and/or controversial issue. Reviews should be prepared as detailed above for a Research Report omitting Introduction through Discussion, and include a Conclusion. When submitting a Review, clearly signify the article as such in the submission title by using: "REVIEW: full article title".

Short Communications
A short communication is an article of original scholarship of unusual interest of less than 1500 words (not including references). An abstract of 100 words or less should be included with no subdivision of text into sections. References should be formatted as above. A total of two tables and/or figures are allowed.

A hypothesis article should be a balanced and insightful consideration of a topic with novel hypotheses well presented and supported. The article should be prepared as a Research Report but without Methods or Results sections.

Book Reviews
Book reviews should be 750 words or less and without sections. Suggestions can be proposed to the Editors-in-Chief.

Letters to the Editor
Authors can submit comments of 1000 words or less concerning prior articles published in KCA to the Editors-in-Chief through the Editorial Office (

Commentaries can be around 1000 words with an abstract and no other subdivisions.


In cover letter
Name, postal address, phone number, fax number and e-mail address of the corresponding author.

Name of an Associate Editor with expertise in the area of the study (if no Associate Editor is suitable, the Editorial Office will handle the submission).

Statement that all authors have contributed to the work, agree with the presented findings, and that the work has not been published before nor is being considered for publication in another journal.

A list of at least 4-6 potential reviewers knowledgeable in the area of the study and potential reviewer conflicts.

Statement that procedures involving experiments on human subjects are done in accord with the ethical standards of the Committee on Human Experimentation of the institution in which the experiments were done or in accord with the Helsinki Declaration of 1975.

Statement that procedures involving experimentation on animal subjects are done in accord with either the guide of the institution in which the experiments were done, or with the National Research Council's guide for the care and use of laboratory animals.

All affiliations with or financial involvement (e.g., employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, royalties) with any organization or entity, independent of relevance to the particular manuscript, are completely disclosed in the letter of submission.

In manuscript

Where applicable, a statement of compliance with guidelines, and inclusion of a flow chart, for respectively

Compliance with guidelines on human experimentation as well as protocol approval by a local Institutional Review Board should be specified.

Compliance with guidelines of animal experimentation as well as protocol approval by the Institutional Animal Care and Use Committee should be specified.

Statement of all financial and material support, independent of relevance to the particular manuscript, and any potential conflicts should also be clearly identified in the Acknowledgment and Conflict of Interest sections. If there is no Conflict-of-Interest then still add this statement.

All financial and material support are clearly identified in the manuscript, including listing of support specified in the letter of submission.

Resubmissions should include the manuscript number and a reference that the paper is a revision. The point-by-point response to the previous reviews should be included at the top of the manuscript.

Authors of published articles (non-prepress, final articles) will be contacted by Kudos. Kudos is a service that helps researchers maximize the impact and visibility of their research. It allows authors to enrich their articles with lay metadata, add links to related materials and promote their articles through the Kudos system to a wider public. Authors will receive no more than three emails: one invitation and a maximum of two reminders to register for the service and link the published article to their profile. Using and registering for Kudos remains entirely optional. For more information, please have a look at our authors section.


Would you like some pointers on how to help your research achieve a wider reach and greater impact? Please consult our Promotional Toolkit for Authors for tips.


Google Scholar

Use of Ibuprofen and Similar NSAIDs May Shorten Life of Patients with Metastatic Renal Cell Carcinoma

01 May 2018 - Amsterdam, NL – Ibuprofen, aspirin, and other non-steroidal anti-inflammatory drugs (NSAIDs) are among the most commonly utilized medications in the United States. Primarily for treating pain, inflammation, and preventing cardiovascular disease, NSAIDs’ promising anti-cancer properties have been highlighted by a growing body of data in recent years. However, a new study in the journal Kidney Cancer indicated that non-aspirin NSAID use was associated with shorter overall survival in patients with metastatic renal cell carcinoma (mRCC)....